The Costs and Reimbursements for Lung Cancer Treatment Among Selected Health Care Providers in the Czech Republic

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F44555601%3A13510%2F14%3A43885799" target="_blank" >RIV/44555601:13510/14:43885799 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/68407700:21460/14:00218471

Výsledek na webu

<a href="http://dx.doi.org/10.15240/tul/001/2014-3-007" target="_blank" >http://dx.doi.org/10.15240/tul/001/2014-3-007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.15240/tul/001/2014-3-007" target="_blank" >10.15240/tul/001/2014-3-007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Costs and Reimbursements for Lung Cancer Treatment Among Selected Health Care Providers in the Czech Republic

Popis výsledku v původním jazyce

The objective of the article is to objectivise and assess the costs for the lung cancer therapy from the payer's (health insurance company) and the healthcare provider?s (hospital) perspective based on information available from several large hospitals and specialised centres. No comprehensive assessment of costs related to the treatment of lung cancers at all stages has been published in the Czech Republic to-date. The results in this study are calculated based on diagnostic and therapeutic algorithms,i.e. process maps. These, in turn, are derived from the recommended therapeutic procedures issued by the Masaryk Institute of Oncology, the University Hospital in Hradec Králové and the University Hospital in Plzeň. In total, the costs and reimbursements were calculated for 32 utilized algorithms, i.e. process maps. The costs for therapeutic processes account for 22 results, while 10 results correspond to diagnostic processes. Both direct and indirect costs were included in individual c

Název v anglickém jazyce

The Costs and Reimbursements for Lung Cancer Treatment Among Selected Health Care Providers in the Czech Republic

Popis výsledku anglicky

The objective of the article is to objectivise and assess the costs for the lung cancer therapy from the payer's (health insurance company) and the healthcare provider?s (hospital) perspective based on information available from several large hospitals and specialised centres. No comprehensive assessment of costs related to the treatment of lung cancers at all stages has been published in the Czech Republic to-date. The results in this study are calculated based on diagnostic and therapeutic algorithms,i.e. process maps. These, in turn, are derived from the recommended therapeutic procedures issued by the Masaryk Institute of Oncology, the University Hospital in Hradec Králové and the University Hospital in Plzeň. In total, the costs and reimbursements were calculated for 32 utilized algorithms, i.e. process maps. The costs for therapeutic processes account for 22 results, while 10 results correspond to diagnostic processes. Both direct and indirect costs were included in individual c

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

AE - Řízení, správa a administrativa

OECD FORD obor

—

Projekt

<a href="/cs/project/NT11532" target="_blank" >NT11532: Hodnocení zdravotnických prostředků</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

E+M. Ekonomie a Management

ISSN

1212-3609

e-ISSN

—

Svazek periodika

17

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

12

Strana od-do

74-85

Kód UT WoS článku

000342261200007

EID výsledku v databázi Scopus

—